Another brick in the wall: The impact of ticagrelor use on the incidence of stroke in a large registry

Abstract

Get full access to this article

View all access options for this article.

References

Ulvenstam A, Henriksson R, Söderström L, et al. Ischemic stroke rates decrease with increased ticagrelor use after acute myocardial infarction in patients treated with percutaneous coronary intervention. Eur J Prev Cardiol 2018; 25: 1219–1230.

D’Ascenzo

Iannaccone

Saint-Hilary

et al.

Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: A network meta-analysis of 64 randomized controlled trials and 102 735 patients. Eur Heart J 2017; 38: 3160–3172.

Wallentin

Becker

Budaj

et al.

PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1045.

Hobbs

Taylor

Jan Geersing

et al.

European Primary Care Cardiovascular Society (EPCCS) SPAF working group. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol 2016; 23: 460–473.

Proietti

Mairesse

Goethals

et al.

Belgian Heart Rhythm Week Investigators. Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. Eur J Prev Cardiol 2017; 24: 328–334.

Wong

Wang

Leng

et al.

Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013; 128: 1656–1666.

Diener

Bogousslavsky

Brass

et al.

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–331.

Bhatt

Fox

Hacke

et al.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1706.

Bonaca

Goto

Bhatt

et al.

Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack using Ticagrelor compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation 2016; 134: 861–871.

10.

Johnston

Amarenco

Albers

et al.

SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375: 35–43.

11.

D’Ascenzo

Colombo

Barbero

et al.

Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: Systematic review and meta-analysis. J Interv Cardiol 2014; 27: 233–241.

12.

Veronesi

Tunstall-Pedoe

Ferrario

et al.

MORGAM Project. Combined effect of educational status and cardiovascular risk factors on the incidence of coronary heart disease and stroke in European cohorts: Implications for prevention. Eur J Prev Cardiol 2017; 24: 437–445.